The Walt Disney Co (DIS) Q2 2025 Earnings Call Highlights: Strong Financial Performance and ...
Q : Can you elaborate on the decision to build a Disney Theme Park in Abu Dhabi and the expected audience? Also, what contributed to the margin improvement in domestic parks? A : We chose Abu Dhabi due to its strategic location, infrastructure, and partnership with Miral Group. The region's accessibility to millions of income-qualified visitors was a key factor. The margin improvement in domestic parks was due to a combination of factors, including cruise mix and underlying park performance.
Q : Bob, can you discuss the impact of integrating Hulu and sports content into Disney+ on engagement and churn? Also, is the three-year guidance for double-digit earnings growth still in place? A : The integration of Hulu and sports content into Disney+ has positively impacted engagement and reduced churn significantly. We aim to turn streaming into a growth business by further integrating Disney+ and Hulu, launching ESPN direct-to-consumer, and investing in technology and content. The long-term guidance for double-digit earnings growth remains intact.
The company acknowledges that producing too much content for streaming platforms has affected quality, particularly in the Marvel segment.
ESPN's Q2 prime time audience among the key 18 to 49 demographic was up 32%, marking its most-watched Q2 in prime time ever.
The Entertainment business, including movies and sports, continues to generate strong growth, with Marvel's Thunderbolts being the number one movie globally.
The Walt Disney Co ( NYSE:DIS ) announced a new Disney Theme Park in Abu Dhabi, expanding its global presence and reaching new audiences.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
ESPN Prime Time Audience: Up 32% among the key 18 to 49 demographic, marking ESPN's most watched Q2 in prime time ever.
Story Continues
Q: Could you share more about the upcoming theatrical slate and Marvel's role in Disney's strategy? A: We have a strong upcoming slate, including live-action Lilo & Stitch, Pixar's Elio, and Marvel's The Fantastic Four. Marvel remains a significant driver, and by focusing more on films, we expect better quality and success, as seen with Thunderbolts.
Q: What are your expectations for the advertising market, and how is the Abu Dhabi park structured financially? A: The advertising market is healthy, with strong demand in live sports and robust upfront interest. The Abu Dhabi park is structured as a license arrangement, with Disney receiving royalties and providing design and operational oversight.
Q: How will ESPN's direct-to-consumer offering differ from linear ESPN, and what features will it include? A: ESPN's direct-to-consumer service will offer additional features like betting and fantasy, differentiating it from linear ESPN. Subscribers will have a seamless experience across Disney+, Hulu, and ESPN, with integrated features enhancing the user experience.
Q: Can you provide an update on the demand environment for the Experiences segment and expectations for fiscal '26? A: The demand for Experiences remains strong, with bookings up for Walt Disney World. While international demand, particularly in China, faces challenges, domestic performance is robust. We expect high single-digit growth for fiscal '25, with guidance for '26 to be provided later.
Q: What are the key learnings from the Disney Treasure cruise launch, and how is international visitation to domestic parks? A: The Disney Treasure cruise has been well-received, with high ratings due to enhanced Disney IP integration. International visitation to domestic parks hasn't returned to pre-COVID levels but remains in double digits, with domestic attendance compensating for any shortfall.
Q: Are there plans for further expansion of Disney parks globally, and how will streaming operating leverage be achieved? A: While no immediate plans exist for an eighth park location, we continue to invest in existing parks and cruise ships. Streaming operating leverage will come from revenue growth and cost reductions, including G&A savings and marketing efficiencies.
Q: How will the $30 billion expansion in Florida and California impact park capacity and returns? A: The expansion aims to enhance guest experience and increase capacity without compromising quality. The return on invested capital in the Experiences segment is at record levels, and we expect continued stellar returns from these investments.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
24 minutes ago
- Axios
New movies and shows this week on Hulu, Netflix and Apple TV+
Here's what's new on Hulu, Netflix, Apple TV+, BET+ and Prime Video. What we're watching: Documentaries about millennial media star Alex Cooper and the Astroworld Festival tragedy and a new thriller starring Julianne Moore and Sydney Sweeney. " Call Her Alex" available now on Hulu State of play: This two-part doc chronicles the life and career of "Call Her Daddy" host Alex Cooper. What she's saying: "It's a behind-the-scenes look at the moments that shaped me — the raw, the messy, the personal stuff I've never felt comfortable sharing until now," Cooper said in a statement. " Trainwreck: The Astroworld Tragedy" available now on Netflix Zoom in: Survivors, paramedics and security personnel recount the 2021 Astroworld Festival crowd crush that left 10 dead. Zoom out: This episode kicks off Netflix's " Trainwreck" anthology — a series of documentaries about some of the biggest disasters that made headlines. " Echo Valley" available Friday on Apple TV+ The intrigue: Julianne Moore and Sydney Sweeney star in this psychological thriller about a woman who goes to great lengths to help her troubled daughter. More new titles " Divorced Sistas" on BET+ This spinoff of "Sistas" about five women in different stages of their romantic lives features a star-studded cast, including LeToya Luckett, DeVon Franklin and RonReaco Lee. Available now " FUBAR" Season 2 on Netflix Carrie-Anne Moss ("The Matrix") guest stars as Greta, the ex-lover and adversary of Luke Brunner (played by Arnold Schwarzenegger). Available now " Deep Cover" on Prime Video " The Fairly OddParents: A New Wish" Season 2 on Netflix Characters from the original Nickelodeon series, including Mr. Crocker, Vicky and Poof, return in the second season of the cartoon's revival. Available now " Underdogs" on Hulu and Disney+ Ryan Reynolds narrates this the five-part series that shows animals on the lower rungs of the food chain, including frogs, honey badgers, shrimp, turkeys and caterpillars. Available Monday " Not a Box" on Apple TV+ This new preschool series about an imaginative rabbit named Riley is based on the picture book of the same name by New York Times bestselling author Antoinette Portis. Available Friday " ROMCON: Who the F**K is Jason Porter?" on Prime Video This true-crime doc follows a Toronto woman who investigates her boyfriend after discovering he is a convicted criminal and romance scammer. Available Friday " Atsuko Okatsuka: Father" on Hulu
Tom's Guide
an hour ago
- Tom's Guide
I used AI to slash my monthly expenses — without giving up the things I love
With high prices and summer expenses creeping in, I knew I had to get serious about my budget. So, naturally I turned to the one assistant I knew wouldn't judge me: AI. Over the course of a month, I used ChatGPT and Gemini to track down hidden spending, negotiate lower bills and rethink the way I plan meals. I wasn't expecting much — just a few dollars shaved here and there. But by the end of the month, I had saved a significant amount. Here's exactly how I did it (without sharing any personal or credit card information). First up: subscription creep. My credit card shows "upcoming" subscriptions, which I copied and pasted into the prompt area. If your credit card doesn't offer this, you can upload a monthly statement and the AI can pick out the subscriptions that way. Once I did that, I used this prompt: 'Analyze this list of monthly subscriptions and suggest which ones I can cancel, pause or downgrade based on usage.' Within seconds, ChatGPT flagged several that I hadn't used in months and didn't even realize I was still paying for, including a fitness app I forgot about, a duplicate cloud storage plan, and an audiobook subscription I was no longer also suggested checking for bundled services (I was paying separately for Hulu and Disney+, despite having access to the bundle). Next, I asked ChatGPT to help me lower my phone bill because for some reason it increased by $20 since the month before. What was that about? I used the prompt: 'Help me write a script to ask my internet provider for a discount or promotion.'It gave me a short, polite message that mentioned my long-time customer status and asked about current promotions. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. I called using that exact script, and after a brief hold, I got a $40/month credit applied for the next 12 months. By doing that, I also got internet with the phone provider and was able to cancel my neighborhood provider; this was something I hadn't thought of. AI also helped me draft cancellation emails for a gym membership with an 'absolutely no refunds' policy (and I got a refund!). Feeding a family of five can add up fast, especially when you don't plan ahead. I asked Gemini to help: 'Create a meal plan for a week of dinners under $100.' My grocery bill is usually about $250. I gave the chatbot a short list of pantry and freezer items, and it filled in the gaps with a budget-friendly grocery list. It suggested sheet pan chicken, chili, tacos and one night of leftovers. The meal plan helped me stick to a grocery budget and eliminated our usual midweek pizza my kids complained about no more takeout pizza, I set up a ChatGPT Task to search the best pizza deals in the area every Friday night. Weekend activities can quietly wreck your budget, especially with kids. Instead of defaulting to movie tickets or amusement parks, I asked ChatGPT: 'Find 5 free or low-cost activities for families this weekend near [my town].' It found a free library event, a nature center with no admission fee and a local museum offering half-price Saturday admission. I also used it to generate indoor activities for a rainy day at home (pillow fort challenge, movie marathon and kitchen bingo). While I would never let AI become my financial planner, or recommend anyone else do that, I will admit, AI is a good assistant when it comes to uncovering extra purchases that I really don't chatbot linked directly to my accounts or tracked real-time spending. You should never give confidential or sensitive personal information to a what it can do is give you a clear-eyed look at your habits, surface savings you might miss and help you act on them with confidence. And in this economy? I'll take AI's two cents.
Yahoo
an hour ago
- Yahoo
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Company Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025 Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention. Event DetailsDate: Tuesday, June 17, 2025Time: 3:15 p.m. ETLocation: Room 153A, Boston Convention & Exhibition Center The Company's lead asset, SkinJect Inc., is a development stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The Company is currently conducting a Phase 2 clinical study SKNJCT-003 in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The Company also announced expanding clinical trial sites in Europe. The Company also has a clinical design (SKNJCT-004) currently underway in United Arab Emirates (UAE). The study is expected to randomize 36 patients in four sites in UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. In April 2025, the Company announced entering into a binding letter of intent to acquire Antev Ltd. ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. For further information contact: Carolyn Bonner, President (610) 636-0184cbonner@ Anna Baran-Djokovic, SVP Investor Relations (305) 615-9162adjokovic@ About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE. In April 2025, the Company also announced entering into a binding letter of intent to acquire Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company's intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at and on SEDAR+ at Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
